TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 32173018
Drug: High concentrate
Normalized name: A Mulsin High Concentrate 300,000unit Emulsion
Approvals — FDA: no, EMA: no, PMDA: no
Description: High concentrate intake (>350 g/d)
Study: 32173018
Drug: Low concentrate
Normalized name: NIACINAMIDE 2 g in 100 mL / ADENOSINE 0.04 g in 100 mL TOPICAL LIQUID [Hydrating all in one glow concentrate ampoule]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low concentrate intake (≤350 g/d)
Study: 34489274
Drug: Sputum samples
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sputum samples collected at baseline and monthly to week 24
Study: 34489274
Drug: PK and
Normalized name: ivacaftor
DrugBank: Ivacaftor (DB08820)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: PK and PKPD models developed for each drug
Study: 34516535
Drug: Inflammation-adjusted ferritin
Normalized name: Inflammation OTC Bruise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inflammation-adjusted ferritin concentrations using a higher ferritin cut-off point (<30 g/L)
Study: 34516535
Drug: Inflammation-adjusted ferritin
Normalized name: Inflammation OTC Bruise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inflammation-adjusted ferritin concentrations excluding subjects with inflammation (C-reactive protein >5 mg/L or a1-acid glycoprotein >1 g/L)
Study: 34516535
Drug: Proportion of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proportion of children with inflammation according to C-reactive protein concentrations >5 mg/L
Study: 34516535
Drug: Proportion of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proportion of children with inflammation according to a1-acid glycoprotein concentrations >1 g/L
Study: 35840306
Drug: Prophylactic antibiotic
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic antibiotic administration 1 week prior to tissue culture collection
Study: 35840306
Drug: Prophylactic antibiotic
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic antibiotic administration 3 days prior to tissue culture collection
Study: 35840306
Drug: Prophylactic antibiotic
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic antibiotic administration 1 day prior to tissue culture collection
Study: 35840306
Drug: Prophylactic antibiotic
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic antibiotic administration 1 day after tissue culture collection
Study: 34472896
Drug: Group cognitive
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group cognitive remediation therapy (CRT)
Study: 34431929
Drug: Floral therapy
Normalized name: floralozone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Floral therapy (Five Flower floral essence)
Study: 35962639
Drug: Midazolam/Ketamine (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam/Ketamine (30 to 50 μg/kg and 0.25 to 1 mg/kg)
Study: 35962639
Drug: Propofol/Fentanyl (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol/Fentanyl (0.5 to 1 mg/kg and 0.5 to 1 mg/kg)
Study: 35389583
Drug: Intense pulsed
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intense pulsed light and radiofrequency therapy
Study: 35220312
Drug: Propolis alone
Normalized name: propolis
DrugBank: Sodium fluorophosphate (DB09484)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propolis alone (1,000 mg/day)
Study: 35220312
Drug: Propolis (1,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propolis (1,000 mg/day) plus melatonin (20 mg/day)
Study: 35220312
Drug: Melatonin alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin alone (20 mg/day)
Study: 36411426
Drug: 0.25% bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.25% bupivacaine (0.4 ml/kg)
Study: 36411426
Drug: 0.125% bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.125% bupivacaine (0.8 ml/kg)
Study: 34786388
Drug: Dexamethasone 8
Normalized name: dexamethasone 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone 8 mg intravenous single dose one hour before TACE
Study: 33098211
Drug: Escitalopram 10
Normalized name: escitalopram 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escitalopram 10 mg orally once daily for 3 months (n = 12)
Study: 35240861
Drug: Endovascular treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endovascular treatment only (Control)
Study: 32920808
Drug: Higher dose
Normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher dose edoxaban (HDER)
Study: 32920808
Drug: Lower dose
Normalized name: flowers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower dose edoxaban (LDER)
Study: 35281950
Drug: PRP+VSD treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: PRP+VSD treatment (group D)
Study: 32565319
Drug: External radiation
Approvals — FDA: no, EMA: no, PMDA: no
Description: External radiation boost (5 × 3 Gy) followed by standard pelvic chemoradiation (25 × 2 Gy with concurrent capecitabine)
Study: 32565319
Drug: Standard pelvic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard pelvic chemoradiation (25 × 2 Gy with concurrent capecitabine) without boost
Study: 34244284
Drug: Mechanical and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mechanical and oral antibiotic bowel preparation (MOABP) - 1g neomycin and 1g metronidazole two times on the day prior to surgery
Study: 34244284
Drug: Mechanical bowel
Normalized name: ascorbic acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mechanical bowel preparation (MBP) - identical placebo
Study: 33159526
Drug: Ticagrelor (180-mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ticagrelor (180-mg loading dose on day 1 followed by 90 mg twice daily for days 2-30) plus aspirin (300 to 325 mg on day 1 followed by 75 to 100 mg daily for days 2 to 30)
Study: 33159526
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus aspirin (300 to 325 mg on day 1 followed by 75 to 100 mg daily for days 2 to 30)
Study: 33159526
Drug: Ticagrelor (180-mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ticagrelor (180-mg loading dose on day 1 followed by 90 mg twice daily for days 2-30) plus aspirin
Study: 35510948
Drug: Test formulation
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test formulation (single 20 mg dose)
Study: 34145906
Drug: Transitional care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transitional care interventions (care continuity and coordination, medication management, symptom recognition, self-management)
Study: 34529026
Drug: Weekly health
Normalized name: Healthy Mama
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly health education via WeChat
Study: 32919110
Drug: Vitamin D3
Normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D3 10 μg/day
Study: 32919110
Drug: Vitamin D3
Normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D3 30 μg/day
Study: 32057576
Drug: MVA‐BN‐RSV high
Approvals — FDA: no, EMA: no, PMDA: no
Description: MVA‐BN‐RSV high dose (1 × 10^8 TCID50)
Study: 32057576
Drug: MVA‐BN‐RSV low
Approvals — FDA: no, EMA: no, PMDA: no
Description: MVA‐BN‐RSV low dose (1 × 10^7 TCID50)
Study: 32057576
Drug: MVA‐BN‐RSV (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: MVA‐BN‐RSV (both doses)
Study: 32057576
Drug: MVA‐BN‐RSV combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: MVA‐BN‐RSV combined high dose groups
Study: 35668121
Drug: Glucose solution
Normalized name: TrueControl Glucose Solution Level 0
DrugBank: Dextrose, unspecified form (DB09341)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glucose solution (reference food, GS)
Study: 34620123
Drug: Oral carbohydrate-rich
Normalized name: omega-3 carboxylic acids Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral carbohydrate-rich (Ch-R) supplement taken 2 hours before elective caesarean delivery
Study: 34477469
Drug: Betaine (BET)
Normalized name: betaine
DrugBank: Betaine (DB06756)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Betaine (BET) supplementation 2.4 g/day for 2 weeks
Study: 34600848
Drug: Standard preoperative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard preoperative antibiotics
Study: 34600848
Drug: Chlorhexidine skin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorhexidine skin preparation and antibiotic pocket wash
Study: 34236435
Drug: Zinc before
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc before breakfast (ZBB) - 25 mg zinc as zinc gluconate taken in the fasted state 30 min before breakfast
Study: 34236435
Drug: Zinc with
Normalized name: Zinc with Vitamin C
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc with breakfast (ZWB) - 25 mg zinc as zinc gluconate taken with breakfast
Study: 32758296
Drug: Bleaching treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bleaching treatment with hydrogen peroxide 35% applied for 2 days (2×1 d)
Study: 32758296
Drug: No bleaching
Approvals — FDA: no, EMA: no, PMDA: no
Description: No bleaching treatment (control group)
Study: 35899811
Drug: RTS,S/AS01 vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: RTS,S/AS01 vaccine (three doses)
Study: 35286196
Drug: RSV vaccine
Normalized name: RSV VACCINE
Approvals — FDA: no, EMA: no, PMDA: no
Description: RSV vaccine administered to pregnant mothers
Study: 36087116
Drug: Phytate group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phytate group (380 mg capsule of calcium‐magnesium InsP6 every 24 h for 3 months)
Study: 32302705
Drug: Antimicrobial photodynamic
Normalized name: GAUZE,ANTIMICROBIAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antimicrobial photodynamic therapy (aPDT) using methylene blue as a photosensitizer activated by red and infrared diode laser
Study: 32302705
Drug: Low-level laser
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-level laser therapy (LLLT) using red and infrared diode laser
Study: 34254834
Drug: Supplementation with
Normalized name: Similac For Supplementation with Iron Powder for Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supplementation with 25 mg vitamin B6 and 400 mg magnesium oxide (S)
Study: 34254834
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of low oxalate diet and B6/magnesium supplementation (DS)
Study: 33323209
Drug: Hourly stand
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hourly stand prompt group
Study: 33323209
Drug: 10,000 daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10,000 daily step prompt group
Study: 34408569
Drug: Sublingual immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual immunotherapy (SLIT) with house dust mite (HDM) for 24 months
Study: 34408569
Drug: Control treatment
Normalized name: SALICYLIC ACID 190 mg in 1 mL TOPICAL LIQUID [Derma E Acne Blemish Control Treatment Serum]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control treatment for 24 months
Study: 34189249
Drug: 70 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 70 mg/day intepirdine
Study: 34189249
Drug: 35 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 35 mg/day intepirdine
Study: 33319444
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg of controlled‐release morphine
Study: 33149896
Drug: 3% NaOCl
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3% NaOCl gel irrigating the canals without PUI
Study: 33149896
Drug: 3% NaOCl
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3% NaOCl gel with PUI
Study: 35649241
Drug: 3.4 g
Normalized name: psyllium 3.4 g oral wafer
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.4 g psyllium fiber supplementation twice a day for 1 week before surgery
Study: 34514692
Drug: DAPA+SAXA+MET (10/5
Approvals — FDA: no, EMA: no, PMDA: no
Description: DAPA+SAXA+MET (10/5 mg)
Study: 34514692
Drug: GLIM+MET (1-6
Approvals — FDA: no, EMA: no, PMDA: no
Description: GLIM+MET (1-6 mg)
Study: 33326891
Drug: Cognitive therapy
Normalized name: cognitive therapy software
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive therapy plus antidepressant medications
Study: 33900493
Drug: Caffeine (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (100 mg three times daily)
Study: 35476316
Drug: Fedratinib 400
Normalized name: FEDRATINIB
DrugBank: Fedratinib (DB12500)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Fedratinib 400 mg/day
Study: 33401384
Drug: Brain Breaks®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brain Breaks® video intervention for 3-5 min daily at low-to-moderate intensity for three months
Study: 32968158
Drug: Thrice-weekly 3,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrice-weekly 3,000 IU cholecalciferol
Study: 32968158
Drug: Once-monthly cholecalciferol
Normalized name: Cholecalciferol
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-monthly cholecalciferol (equivalent to 9,000 IU/week)
Study: 32968158
Drug: Thrice-weekly placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrice-weekly placebo
Study: 32968158
Drug: Once-monthly placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-monthly placebo
Study: 34103317
Drug: Cognitive‐behavioural therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive‐behavioural therapy for insomnia (CBT‐I)
Study: 32534584
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of methoxamine at 2 μg/kg/min
Study: 32534584
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of normal saline (control)
Study: 35257600
Drug: New antiretroviral
Approvals — FDA: no, EMA: no, PMDA: no
Description: New antiretroviral drug as part of a combination antiretroviral treatment regimen
Study: 38231017
Drug: High-dose dexamethasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose dexamethasone (HD-DXM)
Study: 32371539
Drug: Pembrolizumab 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab 200 mg every 3 weeks for three cycles, followed by three adjuvant cycles, in combination with definitive radiotherapy.
Study: 33219482
Drug: SAM vaginal
Approvals — FDA: no, EMA: no, PMDA: no
Description: SAM vaginal gel (intravaginal daily dose for three 28-day periods)
Study: 33219482
Drug: SAM vaginal
Approvals — FDA: no, EMA: no, PMDA: no
Description: SAM vaginal gel
Study: 35672894
Drug: Daily pulmonary
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily pulmonary rehabilitation training including pursed-lip breathing (PLB) training, abdominal breathing training, skeletal muscle training, and coughing and expectoration training.
Study: 35672894
Drug: Routine drug
Normalized name: Peace Out Acne Hero Routine KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine drug therapy, COPD knowledge education, and smoking cessation treatment (Control group).
Study: 34574483
Drug: Hypoglycemia problem-solving
Normalized name: Solv X
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypoglycemia problem-solving program (HPSP), 8-week duration, 90 min weekly sessions
Study: 32913632
Drug: Wet preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wet preparation method
Study: 34365570
Drug: Self-etching (SE)
Normalized name: Selenomethionine Se-75
DrugBank: Selenomethionine Se-75 (DB09400)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-etching (SE) agent 1 with PFS (SE1_PFS_Shofu)
Study: 34365570
Drug: Self-etching (SE)
Normalized name: Selenomethionine Se-75
DrugBank: Selenomethionine Se-75 (DB09400)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-etching (SE) agent with PFS (SE_PFS_Kuraray)
Study: 33197271
Drug: Dulaglutide (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dulaglutide (1.5 mg/weekly)
Study: 36477889
Drug: 1.83 g
Normalized name: HOMOSALATE 3.61 g in 36 g / OCTOCRYLENE 0.98 g in 36 g / OCTISALATE 1.83 g in 36 g / AVOBENZONE 1.1 g in 36 g TOPICAL SPRAY [Sunscreen]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.83 g protein kg body mass−1 day−1 (HIGH)
Study: 36477889
Drug: 1.20 g
Normalized name: OCTINOXATE 1.5 g in 30 g / TITANIUM DIOXIDE 1.20 g in 30 g TOPICAL LOTION [Sun Essential]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.20 g protein kg body mass−1 day−1 (MOD)
Study: 36477889
Drug: 0.94 g
Normalized name: BUPHENYL 0.94 GM/GM Oral Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.94 g protein kg body mass−1 day−1 (LOW)
Study: 32075475
Drug: ASP1707 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: ASP1707 30 mg twice daily
Study: 34579560
Drug: Topiramate (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topiramate (100 mg/day)
Study: 34115064
Drug: Different masses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Different masses of bone substitute (12.5 mg and 25 mg)
Study: 34607285
Drug: Nivolumab 360
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab 360 mg every 3 weeks plus ipilimumab 1 mg/kg every 6 weeks with two cycles of chemotherapy
Study: 34607285
Drug: Chemotherapy alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy alone (four cycles)
Study: 34607285
Drug: Patients who
Normalized name: MAYZENT 0.25mg Tablet Starter Pack (For Patients Who Will Receive The 2mg Maintenance Dosage)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients who discontinued all components of nivolumab plus ipilimumab with chemotherapy treatment due to TRAEs
Study: 32171815
Drug: Educational video
Normalized name: DIABETES PATIENT EDUCATION PACK
Approvals — FDA: no, EMA: no, PMDA: no
Description: Educational video and patient information leaflet targeting misconceptions of topical corticosteroids
Study: 32185840
Drug: ART with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: ART with protease inhibitors (PI)
Study: 32185840
Drug: ART without
Normalized name: threonine
DrugBank: Threonine (DB00156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ART without protease inhibitors (PI)
Study: 32185840
Drug: ART with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: ART with protease inhibitors (PI) after excluding women with detectable viral load and CD4+ T-cell count <200
Study: 32185840
Drug: ART without
Normalized name: threonine
DrugBank: Threonine (DB00156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ART without protease inhibitors (PI) after excluding women with detectable viral load and CD4+ T-cell count <200
Study: 33773357
Drug: Cognitive-behavioral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral therapy for 24 weeks
Study: 33773357
Drug: Cognitive-behavioral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral therapy or supportive psychotherapy
Study: 35816306
Drug: Corticosteroid injection
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroid injection and exercise therapy
Study: 35816306
Drug: Placebo injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo injection and exercise therapy
Study: 34086195
Drug: Provision of
Normalized name: Ex vivo, lentiviral vector (LV)-mediated, genetically modified autologous cell therapy intended for the stable provision of functional human iduronate-2-sulfatase (IDS) enzyme to subjects with Hunter syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Provision of operative treatment post-DGA
Study: 36304817
Drug: FF-20 (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: FF-20 (1000 mg, delivering 192 mg fisetin)
Study: 36304817
Drug: UF (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: UF (1000 mg)
Study: 33025926
Drug: Insulin Syringe
Normalized name: Insulin Syringe
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin Syringe (IS)
Study: 33306564
Drug: Smart-pill bottle
Normalized name: bottlebrush pollen extract
DrugBank: Callistemon citrinus pollen (DB10943)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Smart-pill bottle service
Study: 33306564
Drug: Smart-pill bottle
Normalized name: bottlebrush pollen extract
DrugBank: Callistemon citrinus pollen (DB10943)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Smart-pill bottle service (after excluding 3 participants with drug-drug interactions)
Study: 33306564
Drug: Control arms
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control arms (after excluding 3 participants with drug-drug interactions)
Study: 36041732
Drug: Fructose and
Normalized name: Fructose
DrugBank: Fructose (DB04173)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fructose and rice (2 g/kg of CHOs in a CHO ratio of 1:2)
Study: 36041732
Drug: Glucose and
Normalized name: Glucose and treacle only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose and rice (2 g/kg of CHOs in a CHO ratio of 1:2)
Study: 33772433
Drug: Nebulized magnesium
Normalized name: Hydra-Neb
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulized magnesium sulphate (3 mL of 3.2% MgSO4 every 4 hours for 24 hours)
Study: 32253548
Drug: Multiple-dose intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple-dose intravenous tranexamic acid (TXA) administered before incision, 3, 6, 12, 18, and 24 hours later (Group D)
Study: 32253548
Drug: Multiple-dose intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple-dose intravenous tranexamic acid (TXA) (Group D)
Study: 32498372
Drug: Probiotic Lactobacillus
Normalized name: Probiotic Lactobacillus Acidophilus Caplets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic Lactobacillus casei Shirota (LcS), three times daily for six months
Study: 33451648
Drug: High-density peptide
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-density peptide arrays screening of twelve leading vaccine candidates as overlapping 15-mer peptides.
Study: 34928484
Drug: Ramucirumab (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ramucirumab (10 mg/kg intravenously every 2 weeks) plus Erlotinib (150 mg/day orally)
Study: 34928484
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus Erlotinib (150 mg/day orally)
Study: 36881395
Drug: Guideline-directed medical
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guideline-directed medical therapies (GDMT)
Study: 34189606
Drug: Oral Health
Normalized name: CETYLPYRIDINIUM CHLORIDE 0.07 g in 100 mL ORAL RINSE [Assured Oral Health Fresh Mint]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Health Education and Prevention Program (OHEPP)